



Kondor Pharma publishes results of a clinical study on COVID-19 patients treated with Inlawell[®], a proprietary immune support formulation

FOR IMMEDIATE RELEASE

MISSISSAUGA, Ontario (February 28, 2022) – Kondor Pharma Inc. is pleased to announce the publication of its clinical trial results on moderate COVID-19 patients which demonstrates the efficacy of Inlawell[®], its recently developed K-Vie[™]-based immune support formulation. The study has been published online (ahead of print) in the peer-reviewed journal, **Inflammopharmacology**, 2022 Feb 24; 1-11, and is titled: [*Inlawell[®] improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial.*](#)

COVID-19 remains a significant global threat to public health. Despite the availability of vaccines and antiviral drugs, there is still a great need for alternative treatments to help prevent and/or manage COVID-19 symptoms and the underlying dysregulated immune response. We aimed to assess whether the administration of Inlawell[®] syrup would reduce the excessive inflammatory response following SARS-Cov2 infection and thereby prevent severe forms of the disease. In this randomized, placebo-controlled, double-blind clinical study we assigned forty-seven (47) hospitalized patients with moderate COVID-19 to either the Inlawell[®] syrup or placebo. Clinical symptoms, hospitalization stay, immune health and markers of inflammation were evaluated.

Our clinical trial revealed a rescue of the COVID-19-related reduced oxygen levels and shorter hospitalization in patients who received Inlawell[®] compared to placebo. Hematology analysis showed a significant decrease in the neutrophil-to-lymphocyte ratio (NLR) levels, associated with a significant increase in the percentage of lymphocytes in the Inlawell[®] group, thus indicating that Inlawell[®] boosts immune support against the viral infection. Inlawell[®] also decreased significantly the blood levels of key inflammatory cytokines such as IL-6 that are correlated with disease severity in COVID-19 patients.

“We are so pleased with the outcome of this study and hope to make Inlawell[®] available in North America in the near future. Inlawell[®] is designed to protect our body against viral infections such as COVID-19 and influenza and addresses the global demand for such products,” said Dr. Ali Riazi, CEO of Kondor Pharma. The Inlawell[®] syrup formulation was developed at the company’s R&D facility in Mississauga and tested in a clinical trial through collaboration with investigators in the Middle East. Kondor Pharma will provide updates on the product availability in Canada and in the US in the near future.

About Kondor Pharma

Kondor Pharma Inc. is a Canadian health product developer and manufacturer providing natural, plant-based health products that harness the power of boswellia to address a variety of inflammation-related conditions.

For more information, please contact:

Ali Riazi, CEO, Kondor Pharma Inc.
ali.riazi@kondorpharma.com
www.kondorpharma.com

###